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BACKGROUND AND OBJECTIVES: Postdischarge treatment of complicated pneumonia includes

abstract

antibiotics administered intravenously via a peripherally inserted central venous catheter
(PICC) or orally. Antibiotics administered via PICC, although effective, may result in serious
complications. We compared the effectiveness and treatment-related complications of
postdischarge antibiotics delivered by these 2 routes.
METHODS: This multicenter retrospective cohort study included children ≥2 months and <18

years discharged with complicated pneumonia between 2009 and 2012. The main exposure
was the route of postdischarge antibiotic administration, classified as PICC or oral. The
primary outcome was treatment failure. Secondary outcomes included PICC complications,
adverse drug reactions, other related revisits, and a composite of all 4 outcomes, termed “all
related revisits.”
RESULTS: Among 2123 children, 281 (13.2%) received antibiotics via PICC. Treatment failure
rates were 3.2% among PICC and 2.6% among oral antibiotic recipients and were not
significantly different between the groups in across-hospital-matched analysis (matched
odds ratio [OR], 1.26; 95% confidence interval [CI], 0.54 to 2.94). PICC complications
occurred in 7.1%. Adverse drug reactions occurred in 0.6% of children; PICC antibiotic
recipients had greater odds of adverse drug reaction in across hospital matched analysis
(matched OR, 19.1; 95% CI, 4.2 to 87.3). The high rate of PICC complications and differences
in adverse drug reactions contributed to higher odds of the composite outcome of all related
revisits among PICC antibiotic recipients (matched OR, 4.71; 95% CI, 2.97 to 7.46).
CONCLUSIONS: Treatment failure rates between PICC and oral antibiotics did not differ.

Children with complicated pneumonia should preferentially receive oral antibiotics at
discharge when effective oral options are available.
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WHAT’S KNOWN ON THIS SUBJECT: Postdischarge treatment
of complicated pneumonia includes antibiotics administered
intravenously via a peripherally inserted central venous
catheter (PICC) or orally. Postdischarge antibiotics
administered via PICC, although effective, may result in serious
complications.
WHAT THIS STUDY ADDS: Treatment failure rates were low
(2.7%) and not signiﬁcantly different between PICC and oral
antibiotic therapy recipients. PICC complications occurred in
7.1% of children resulting in signiﬁcantly higher adjusted revisit
rates among those receiving PICC (17.8%) versus oral (3.1%)
antibiotics.
To cite: Shah SS, Srivastava R, Wu S, et al. Intravenous Versus Oral Antibiotics
for Postdischarge Treatment of Complicated Pneumonia. Pediatrics. 2016;
138(6):e20161692
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Community-acquired pneumonia is
the most common, serious childhood
infection requiring hospitalization.1,2
Up to 15% of children hospitalized
with pneumonia develop pleural
effusion or empyema (ie, complicated
pneumonia).3,4 Treatment may
include pleural drainage but
almost always requires prolonged
antibiotic therapy.1,5,6 Antibiotics are
typically administered intravenously
during the hospitalization but
can be continued either orally or
intravenously via a peripherally
inserted central catheter (PICC) after
hospital discharge.
Prolonged intravenous antibiotics
administered via PICC, although
effective, may result in serious
complications (eg, catheter-associated
bloodstream infections, venous
thrombosis) and additional health care
utilization (eg, evaluation for fever
necessitating hospital admission).7–9
Oral antibiotics have proven effective
compared with antibiotics via PICC for
other bacterial infections such as acute
osteomyelitis.10 National guidelines
do not directly address the preferred
route of postdischarge antibiotic
therapy in children with complicated
pneumonia but instead highlight
the risks of PICC complications and
emphasize the safety and effectiveness
of oral therapy in other serious
infections.1 Only 1 single-center study
has addressed the effectiveness of
PICC compared with oral antibiotic
therapy in children with complicated
pneumonia.11
Our objectives were to compare
the effectiveness of postdischarge
oral versus intravenous antibiotics
delivered via a PICC for children
with complicated pneumonia and to
determine differences in treatmentrelated complications.

METHODS
Study Design and Data Source
This retrospective cohort study
used data from the Pediatric Health
Information System (PHIS), which

contains hospital administrative and
billing data from children’s hospitals
affiliated with the Children’s Hospital
Association (Overland Park, KS).12,13
We supplemented the PHIS data with
information from the medical record
to (1) confirm eligibility, (2) determine
postdischarge antibiotic choice and
route, (3) review reasons for return
emergency department (ED) visits
and rehospitalizations within 14 days
after index discharge, and (4) identify
causative bacteria from blood and
pleural fluid culture. These data were
collected and managed using secure,
Web-based Research Electronic Data
Capture (REDCap, Nashville, TN) tools
and subsequently merged with PHIS
data.14

Participants
We queried PHIS for children who
(1) were ≥2 months and <18 years
of age on the date of admission; (2)
were discharged between January 1,
2009, and December 31, 2012; and
(3) had an International Classification
of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) discharge
diagnosis code for both pneumonia
(480.×–483.×, 485.×–487.×) and
pleural effusion (510.0, 510.9, 511.0,
511.1, 511.9) where the primary ICD9-CM code was either pneumonia or
pleural effusion (Fig 1).15 If a child
had multiple hospitalizations within
a 14-day period, the first admission
was considered the eligible
encounter, whereas subsequent
admissions were classified as
readmissions.
We used PHIS data to exclude
children from the study cohort
if they (1) had a concurrent or
previous ICD-9-CM code for a chronic
condition that would increase the
risk of treatment failure with either
modality or preclude oral antibiotic
use (ie, cardiovascular, respiratory,
hematology, immunodeficiency,
or malignancy)16; (2) were not
admitted through the ED, thus
excluding most children transferred
from another hospital for whom

pretransfer data would neither be
available in PHIS nor consistently
available in the medical records; (3)
did not receive antibiotics on the
first day of hospitalization, making
it unlikely that they had bacterial
pneumonia at presentation; (4) had
a length of stay <4 days, which might
increase the likelihood of discharge
with intravenous antibiotics for
prolonged therapy, or >14 days,
which might increase the likelihood
of discharge with oral antibiotics
as planned antibiotic therapy was
nearly complete; or (5) transferred
to another facility or expired during
their hospitalization (Fig 1).
Investigators from 38 hospitals
attended a webinar to receive training
on eligibility criteria, relevant data
elements, and use of the REDCap
database.10 Sites received lists of
patients and hospitalizations for
medical record review based on
eligibility criteria applied to PHIS data,
including the index hospitalization
(ie, eligible encounter) as well as all
return visits (ED or hospitalization)
up to 14 days after index discharge.
Children were then excluded based
on medical record review if they
(1) had a medical record that was
not reviewed, (2) had a record that
could not be located, (3) did not
have complicated pneumonia (to
qualify for a diagnosis of complicated
pneumonia on medical record review,
a patient had to have pneumonia
with pleural effusion or empyema
documented on chest radiograph),
(4) had exclusion criteria identified
during medical record review (eg,
transferred from another hospital, no
antibiotics prescribed at discharge,
comorbidities not identified by ICD9-CM codes), or (5) had data quality
issues (eg, intravenous antibiotics at
discharge but no documentation of
PICC placement).

Main Exposure
The main exposure, determined
by medical record review, was the
route of postdischarge antibiotic
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FIGURE 1
Flowchart of the study cohort.

administration, classified as PICC or
oral. If a PICC was placed during the
index hospitalization but removed
before discharge and the child
was prescribed oral antibiotics at
discharge, the child was classified as
receiving oral therapy. Our data-use
agreement did not permit disclosure
of individual hospital performance
in an identifiable manner. Therefore,
hospital-level PICC use is presented in
a deidentified manner but grouped by
US Census Bureau Census Divisions to
permit geographic comparisons.17

Outcome Measures
Outcomes were verified by medical
record review. The main outcome
was treatment failure, defined as an
ED revisit or rehospitalization that
resulted in extension or change of
antibiotic therapy or performance of
pleural drainage. Secondary outcomes
included (1) PICC complications,

defined as fever evaluation, PICC
insertion site or bloodstream
infection, sepsis, or PICC thrombosis;
(2) adverse drug reactions, defined as
diarrhea, Clostridium difficile infection,
rash, erythema multiforme or StevensJohnson syndrome, anaphylaxis,
drug-induced neutropenia, drug fever,
acute kidney injury, serum sickness,
or other drug-related complications;
(3) ED revisits or rehospitalizations
not classified as treatment failure,
PICC complication, or adverse drug
reaction but plausibly related to the
index encounter or treatment (eg,
chest pain, chest tube site drainage);
and (4) a composite outcome
measure of treatment failure, PICC
complication, adverse drug reaction,
and other plausibly related ED revisits
or rehospitalizations.

Covariates
PHIS provided information on age,
sex, race/ethnicity, insurance, and

pleural drainage procedures (ICD9-CM procedure codes 34.04, 34.06,
34.09, 34.21, 34.51, 34.52, 34.91).5
Pleural drainage was classified as
none, chest tube, or surgical (ie,
video-assisted thoracoscopic surgery
or thoracotomy). Pleural drainage
timing was classified as early (ie,
performed ≤2 days after admission)
or late (ie, performed >2 days after
admission) based on the index
procedure performed. Medical record
review provided results of blood
and pleural fluid cultures as well as
discharge antibiotics. Cephalosporins,
antistaphylococcal penicillins, and
β-lactam/β-lactamase inhibitors (eg,
ampicillin-sulbactam, amoxicillinclavulanate) were classified as anti–
methicillin-susceptible Staphylococcus
aureus (MSSA) agents. Clindamycin,
newer generation fluoroquinolones
(eg, levofloxacin, moxifloxacin),
linezolid, and vancomycin were
classified as anti–methicillin-resistant
S. aureus (MRSA) agents.
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Statistical Methods

TABLE 1 Study Population Characteristics Pre- and Postmatch

Matching

Characteristica

Matching balanced patient level
covariates in the PICC and oral
antibiotic groups. Patient-level
covariates were incorporated in
a logistic regression for whether
a patient received PICC or oral
antibiotics to generate a propensity
score for treatment. This model
included the following patient-level
covariates: age, race, insurance,
length of stay in days, blood culture
results (culture negative vs culture
positive), ICU admission, and timing
and route of pleural drainage. To
ensure the best matches on patient
level factors, matching was done
across hospitals because the number
of patients assigned to PICC and oral
groups within each hospital was
sparse.
To make use of all possible
observations while minimizing
differences across observations,
we used full matching based on
these propensity scores.18–20 Full
matching links each PICC-treated
child to the oral therapy-treated
child with the closest propensity
score, or vice versa, in a manner
that results in varying numbers
of matches in each resulting
set. Then we weighted children
receiving oral antibiotics in each
matched set to standardize results
to the characteristics of the PICC
children. Finally, we compared the
weighted characteristics of the
PICC and the oral therapy children
to determine the degree of balance
between the 2 samples. Propensity
score modeling and full matching
were implemented using the
program fullmatch in the R software
package version 3.1 (https://
github.com/markmfredrickson/
optmatch).

Response Models
Both stratified approaches and
marginal models were used to generate
the results for the response model. The
stratified approaches condition on the

n
Age <5 y
White race
Government payer
Length of stay (d)
Culture positive
ICU admission
Drainage procedure
No drainage
Late surgical drainage
Early surgical drainage
Late chest tube drainage
Early chest tube drainage
a
b

Postmatchb

Prematch
Oral

PICC

Oral

PICC

1842
56.0
57.7
54.0
7.2
12.4
18.1

281
61.6
65.5
36.3
9.1
24.6
26.3

1842
61.1
62.4
35.3
9.2
23.9
27.0

281
61.6
65.5
36.3
9.1
24.6
26.3

61.0
11.7
14.9
4.6
7.9

24.6
15.3
19.2
15.3
25.6

24.5
14.8
21.4
12.1
27.2

24.6
15.3
19.2
15.3
25.6

Values presented as percentages except for length of stay, for which mean values are presented.
Percentages are weighted.

matched set but dropped subjects if a
matched set did not contain patients
with differing outcomes. By contrast,
marginal models used all patients
without stratification, thus matching
and the weighting resulted in 2 groups
of patients who were similar except
for route of antibiotic therapy on
discharge.
Odds ratios were generated by
the conditional logistic regression.
As a secondary analysis, we used
weighted logistic regression
to estimate standardized risk
differences for the effect of PICC on
outcomes.21 All variance estimates
and confidence bounds were
confirmed using robust variances.22
All response models and resampling
was performed using the
programs logit, clogit, and
bootstrap, and with a custom
program for this application, all
using Stata v 13.1 (Stata Corp,
College Station, TX).

RESULTS
We identified 7280 eligible
encounters from 38 hospitals. We
excluded 4550 encounters that
met exclusion criteria derived
from PHIS and an additional 607
encounters that met exclusion
criteria derived from medical
record review, including 103

encounters from the 2 hospitals
that did not review any records and
33 encounters from 2 hospitals that
were unable to review records for
some patients in the required study
timeframe (Fig 1). The remaining
2123 children from 36 hospitals
were included. Of these, 1241
(58.5%) were white, 338 (15.9%)
black, 135 (6.5%) Asian or Native
American, and 409 (19.3%) other
race (Table 1); 498 (23.5%) were
classified as Hispanic ethnicity.
The median age was 5.0 years
(interquartile range, 2.0–8.0).
Pleural drainage was performed in
931 (43.9%) children. A pathogen
was identified in blood or pleural
fluid culture in 305 (14.4%) children.
The most common pathogens were
Streptococcus pneumoniae (n = 175),
Staphylococcus aureus (n = 77),
Streptococcus pyogenes
(n = 21), and Streptococcus milleri
group bacteria (n = 9). MRSA
comprised 56 (72.7%) of the S aureus
isolates. The median hospital length
of stay was 7 days (interquartile
range, 5–10). The hospital-level
median length of stay ranged from 5
to 9.5 days, with a median of hospital
medians of 7.0 days.
Overall, 281 (13.2%) children
received antibiotics via PICC
postdischarge. PICC use
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(0.1%), 2 receiving oral antibiotics
and 1 receiving PICC antibiotics,
developed a bronchopleural
fistula.

FIGURE 2
Variation within and across the 9 US Census Divisions in hospital-level PICC rates at discharge for
treatment of pneumonia (n = 36 hospitals). Circles (individual hospital PICC %) have sizes proportional
to the number of patients in the sample, and they are slightly jittered to view overlapping hospitals.
Census division percentages (+) represent the PICC rates for all patients in the region.

postdischarge varied across
hospitals, ranging from 0% to
71%. PICC use also varied within
and among census regions (Fig
2). The most common antibiotics
administered via PICC were antiMSSA antibiotics alone (n = 117,
41.6%); an anti-MSSA antibiotic
plus an anti-MRSA antibiotic
(n = 73, 26.0%); and anti-MRSA
antibiotics alone (n = 42, 14.9%).
The most common antibiotics
administered orally were antiMSSA agents alone (n = 462,
25.1%); anti-MRSA agents alone
(n = 422, 22.9%); anti-MRSA
agent in combination with an antiMSSA agent (n = 261, 14.2%); and
amoxicillin alone (n = 214, 11.6%).
Postdischarge antibiotics were
prescribed for a median of 14 days
(interquartile range, 7–14 days);
5% of subjects were prescribed
21 or more days of antibiotics
postdischarge. No patient in whom
a pathogen was identified received
discordant therapy at discharge.

Before matching, children with
postdischarge PICC antibiotic
therapy had higher rates of
surgical drainage, ICU admission,
and positive cultures (Table 1).
Treatment failure before matching
occurred in 57 (2.7%) children
overall, 3.2% in those with PICC
antibiotic therapy and 2.6% in
those with oral antibiotic therapy
(Table 2). No treatment failures
occurred among the 77 patients
with S aureus isolated. Among
children discharged with oral
antibiotic therapy for culturenegative infection, treatment failure
occurred in 1.4% and 1.9% of those
discharged with amoxicillin and
anti-MRSA antibiotics, respectively.
Management of treatment failure
included pleural drainage (n =
28, 49.1% of treatment failures),
change in antibiotics for new or
persistent symptoms (n = 18,
31.6%), extension of antibiotic
course for persistent symptoms
(n = 3, 5.3%), or other reasons
(n = 8, 14.0%). Three children

PICC complications, which occurred
in 20 (7.1%) children, included PICC
thrombosis resulting in malfunction
(n = 11), PICC dislodgement or
breakage (n = 4), insertion site
cellulitis (n = 1), and fever evaluation
(n = 1); details of the complications
were not available for 3 patients.
No PICC-associated bloodstream
infections were reported. Adverse
drug reactions occurred in 13 (0.6%)
children overall; 6 had a rash, 2
had gastrointestinal symptoms
(abdominal pain), and 1 each
developed serum sickness, druginduced neutropenia, drug fever,
heparin-induced thrombocytopenia,
and joint pain. Other related visits
occurred in 73 (3.4%) of children.
The most common reasons included
respiratory complaints (eg,
tachypnea, cough; n = 29), vomiting/
dehydration (n = 18), chest pain (n =
10), chest tube site drainage (n = 4),
abdominal pain (n = 2), and seizure
(n = 2).
Matching resolved differences in
patient characteristics, including
rates and timing of pleural drainage
(Table 1). After matching, there
were no significant differences in
treatment failure rates between
PICC and oral antibiotic recipients
(matched odds ratio [OR], 1.26; 95%
confidence interval [CI], 0.54 to
2.94) (Table 2). In matched analysis,
adverse drug reactions, other related
revisits (ie, revisits not related to
treatment failure, adverse drug
reactions, or PICC complications),
and all revisits related to complicated
pneumonia remained significantly
higher in those receiving antibiotics
via PICC compared with the oral
route (Table 2).

DISCUSSION
This multicenter study included
>2000 children with complicated
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TABLE 2 Outcomes of Children With Complicated Pneumonia
Outcome
Treatment failure
PICC
Oral
PICC Complications
PICC
Oral
Adverse drug reaction
PICC
Oral
Other related revisits
PICC
Oral
All related revisits
PICC
Oral

Unadjusted Rates,
% (n)

Matched OR (95% CI)a

P

Adjusted Rates, %b

Matched Risk
Difference (95% CI)c

P

3.2 (9)
2.6 (48)

1.26 (0.54 to 2.94)
—

>.2
—

3.2
1.4

1.8% (–0.4 to 3.9)
—

.1
—

7.1 (20)
N/A

—
N/A

—
N/A

—
N/A

—
N/A

—
N/A

3.2 (9)
0.2 (4)

19.1 (4.2 to 87.3)
—

<.001
—

3.2
0.01

3.1% (0.01 to 5.2)
—

.003
—

6.1 (17)
3.0 (56)

3.27 (1.65 to 6.48)
—

.001
—

6.0
1.6

4.4% (1.5 to 7.4)
—

.003
—

17.8 (50)
5.8 (106)

4.71 (2.97 to 7.46)
—

<.001
—

17.8
3.1

14.8% (10.1 to 19.3)
—

<.001
—

N/A, not applicable; —, X.
a ORs estimated from condition logistic regression stratiﬁed by the matched sets. An OR >1 means that the PICC route has a higher risk for the adverse outcome.
b Rates are standardized by weighting matched sets by the number of PICC patients and analyzed using weighted logistic regression with robust variance estimates translated to
probabilities and their differences
c Estimated using weighted logistic regression. A risk difference of greater than 0 means that the PICC route has the higher risk for the adverse outcome.

pneumonia treated at 36 children’s
hospitals. Although PICC use was
not common overall, there was
substantial variation in postdischarge
PICC use across participating
hospitals. Treatment failure rates
were not significantly different
between those treated with PICC
versus oral antibiotics at discharge.
However, children discharged with
PICCs experienced a high rate of
PICC complications and adverse
drug reactions, resulting in high
rates of ED revisits and hospital
readmissions.
We found substantial variation
in PICC use in children with
complicated pneumonia. Although
patient and disease characteristics
contribute to such variation,
clustering of treatment strategies by
hospital suggests that institutional
factors are major determinants of
care practices. Highlighting these
differences in PICC use is a first
step toward reducing unwarranted
variation.
National guidelines recommend
2 to 4 weeks of antibiotic therapy
for complicated pneumonia.1 The
optimal route of antibiotic therapy
has been a source of considerable

debate. National guidelines highlight
the effectiveness of oral antibiotics
for other serious bacterial infections
but emphasize the absence of
comparative data in children
with complicated pneumonia.1
Although effective treatment
of children with complicated
pneumonia requires adequate
antibiotic concentrations in the
lung and pleural space, parenteral
therapy may not be necessary.
Antibiotics such as amoxicillin,
clindamycin, and linezolid have
excellent bioavailability after oral
ingestion and provide appropriate
coverage for salient pathogens.
Only 1 previous study compared
oral with intravenous antibiotics
for complicated pneumonia.11
Stockmann et al examined outcomes
of 391 children hospitalized with
complicated pneumonia at a single
center; 337 (86%) children received
antibiotics via PICC.11 Postdischarge
pneumonia-related complications,
using a comparable treatment
failure definition, occurred in 5
(2%) patients discharged with
antibiotics via PICC and 2 (4%; P =
.25) patients discharged with oral
antibiotics. In our multicenter study,
differences in treatment failure rates

between the PICC and oral antibiotic
groups were not significant. For the
matched analysis, children on oral
antibiotics had a 1.8 percentage
point lower risk of treatment failure.
Although this result is not significant
at conventional levels, the lower
bound of the 95% CI (–0.4% points)
suggests that we can rule out oral
antibiotics as having a greater
risk of treatment failure of clinical
importance.
We divided therapy complications
into PICC-associated complications
and adverse reactions from
antibiotics. The high rate of PICC
complications (7.1%) contributed
to the significantly high rate of all
revisits among children receiving
antibiotics via PICC. In contrast,
Stockmann et al found that while
PICC complications occurred in
5% of patients with complicated
pneumonia, differences in overall
treatment-related complications
between patients receiving oral
(5.6%) or PICC (7.7%, P = .78)
antibiotics were not significant.11 In
our study, adverse drug reactions,
while low overall, occurred more
commonly among those receiving
antibiotics via PICC. Although
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adverse drug reactions are often
considered unavoidable, our data
highlight that the route of therapy,
primarily by virtue of antibiotic
selection, can contribute to their
preventability.
This study had several limitations.
First, as with any observational
study, we could not account for
some variables associated with
illness severity, such as size and
character of the pleural effusion or
presence of necrotizing pneumonia.
These variables may be associated
with both treatment decisions (eg,
need for pleural drainage) and
outcomes. We believe that our
large multicenter sample and the
analytic approaches to address
confounding minimize the impact
of this limitation. A randomized
clinical trial may better balance
unmeasured confounders than our
observational study. However, we
believe that such a trial is unlikely
given ethical considerations and
institutional bias to participation
as suggested by clustering of
postdischarge PICC use by center.
Second, we matched across
hospitals because the paucity
of patients with PICCs at some
hospitals precluded within hospital
matching. This limitation made
it more challenging to account
for hospital-level differences;
however, matching across hospitals
more effectively accounts for
confounding by indication than
matching within hospitals. The
influence of hospital-level factors
on outcomes is mitigated by the low
rate of treatment failures overall.
Third, the frequency and severity
of adverse drug events depend, in
part, on the antibiotic received.
Thus, the differences in the types
of antibiotics received rather than
the route of antibiotic therapy per
se may explain the higher rates of
adverse drug reactions in those
receiving antibiotics via PICC.
Nevertheless, the higher rate of
adverse drug reactions in the PICC

group should be considered when
determining route of antibiotic
therapy postdischarge. Finally, we
were not able to assess revisits to
primary care. Children receiving
oral antibiotics may be more likely
than those receiving intravenous
antibiotics to seek care in the
primary setting when adverse
events occur. If some of these
adverse events did not result in
an ED revisit or rehospitalization,
we may have underestimated
the occurrence of adverse drug
events or other complications in
the oral therapy group. However,
such events may be less serious,
an important consideration when
weighing risks and benefits of oral
versus PICC antibiotic treatment
options.

CONCLUSIONS
Differences in treatment failure
rates between PICC and oral
antibiotic recipients were not
significant. However, adverse
drug reactions and PICCassociated complications
contributed to the higher rates
of reutilization among PICC
antibiotic recipients. Although
antibiotics via PICC may be
appropriate for select patients,
our study highlights the importance
of preferentially treating children
with complicated pneumonia
with oral antibiotics at discharge
when effective oral options are
available.
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